Abstract
Most animal models of contused, compressed or transected spinal cord injury (SCI) require a laminectomy to be performed. However, despite advantages and disadvantages associated with each of these models, the laminectomy itself is generally associated with significant problems including longer surgery and anaesthesia (related post-operative complications), neuropathic pain, spinal instabilities, deformities, lordosis, and biomechanical problems, etc. This review provides an overview of findings obtained mainly from our laboratory that are associated with the development and characterization of a novel murine model of spinal cord transection that does not require a laminectomy. A number of studies successfully conducted with this model provided strong evidence that it constitutes a simple, reliable and reproducible transection model of complete paraplegia which is particularly useful for studies on large cohorts of wild-type or mutant animals - e.g., drug screening studies in vivo or studies aimed at characterizing neuronal and non-neuronal adaptive changes post-trauma. It is highly suitable also for studies aimed at identifying and developing new pharmacological treatments against aging associated comorbid problems and specific SCI-related dysfunctions (e.g., stereotyped motor behaviours such as locomotion, sexual response, defecation and micturition) largely related with ‘command centers’ located in lumbosacral areas of the spinal cord.
Keywords: Model of spinal cord injury, murine model, micturition, central pattern generator, SpinalonTM, loss of voluntary ambulation, locomotion.
Current Pharmaceutical Design
Title:A Valuable Animal Model of Spinal Cord Injury to Study Motor Dysfunctions, Comorbid Conditions, and Aging Associated Diseases
Volume: 19 Issue: 24
Author(s): Pascal Rouleau and Pierre A. Guertin
Affiliation:
Keywords: Model of spinal cord injury, murine model, micturition, central pattern generator, SpinalonTM, loss of voluntary ambulation, locomotion.
Abstract: Most animal models of contused, compressed or transected spinal cord injury (SCI) require a laminectomy to be performed. However, despite advantages and disadvantages associated with each of these models, the laminectomy itself is generally associated with significant problems including longer surgery and anaesthesia (related post-operative complications), neuropathic pain, spinal instabilities, deformities, lordosis, and biomechanical problems, etc. This review provides an overview of findings obtained mainly from our laboratory that are associated with the development and characterization of a novel murine model of spinal cord transection that does not require a laminectomy. A number of studies successfully conducted with this model provided strong evidence that it constitutes a simple, reliable and reproducible transection model of complete paraplegia which is particularly useful for studies on large cohorts of wild-type or mutant animals - e.g., drug screening studies in vivo or studies aimed at characterizing neuronal and non-neuronal adaptive changes post-trauma. It is highly suitable also for studies aimed at identifying and developing new pharmacological treatments against aging associated comorbid problems and specific SCI-related dysfunctions (e.g., stereotyped motor behaviours such as locomotion, sexual response, defecation and micturition) largely related with ‘command centers’ located in lumbosacral areas of the spinal cord.
Export Options
About this article
Cite this article as:
Rouleau Pascal and Guertin A. Pierre, A Valuable Animal Model of Spinal Cord Injury to Study Motor Dysfunctions, Comorbid Conditions, and Aging Associated Diseases, Current Pharmaceutical Design 2013; 19 (24) . https://dx.doi.org/10.2174/1381612811319240010
DOI https://dx.doi.org/10.2174/1381612811319240010 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Applications for Using Stem Cells in Spine Surgery
Current Stem Cell Research & Therapy Computer-Aided Drug Discovery (CADD) Approaches for the Management of Neuropathic Pain
Current Topics in Medicinal Chemistry Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Causal Mechanisms Underlying Periventricular Leukomalacia and Cerebral Palsy
Current Pediatric Reviews The Nitric Oxide Signaling Pathway in the Penis
Current Pharmaceutical Design TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Current Neuropharmacology New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Current Alzheimer Research Molecular Mechanism of Aniline Induced Spleen Toxicity and Neuron Toxicity in Experimental Rat Exposure: A Review
Current Neuropharmacology Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Perspectives of Medieval Persian Medicine on Multiple Sclerosis
Current Drug Metabolism Editorial [Hot Topic: The Administration of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Dentistry (Executive Editor: Saynur Vardar)]
Current Pharmaceutical Design